Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

NCT04429321 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped failure to accrue

Conditions

Renal Cell Carcinoma
Renal Cell Carcinoma Stage IV

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DEVICE: bland embolization

Sponsor

Abramson Cancer Center at Penn Medicine